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Evidence for abnormal calcium homeostasis in patients with adynamic
bone disease. To investigate whether the derangements in calcium kinetics
in patients with renal osteodystrophy are similar in the various histologic
forms of this metabolic bone disease, 43 patients on chronic maintenance
dialysis underwent calcium kinetic studies using the double isotope
technique, iliac crest bone biopsies for mineralized bone histology and
histomorphometry and determinations of serum indices of calcium and
bone metabolism. Intestinal calcium absorption was not different among
the three histologic groups. However, women exhibited lower calcium
absorption in each histologic form (P < 0.01). Patients with predominant
hyperparathyroid bone disease showed plasma calcium efflux, calcium
accretion rate and calcium retention markedly above normal values.
Patients with low turnover bone disease exhibited a normal or slightly
decreased plasma calcium efflux and calcium accretion rate together with
a disproportionately low calcium retention. Patients with mixed uremic
osteodystrophy presented with a calcium kinetic profile intermediary to
the two other forms. Good relationships existed between plasma calcium
efilux, calcium accretion rate, calcium retention and histomorphometric
parameters of bone turnover as well as serum levels of parathyroid
hormone. However, no serum parameter could indicate with certainty the
underlying bone disease. These findings demonstrate that adynamic bone
disease does not merely represent an academic finding but is characterized
by a very low bone capacity to buffer calcium and inability to handle an
extra calcium load. This is particularly relevant for the daily care of
end-stage renal failure patients presently receiving higher than ever
amounts of vitamin D and calcium salts.
Control of calcium and bone homeostasis remains a major
challenge to the nephrologist caring for patients on chronic
dialysis. Patients on dialysis present either with low, normal or
elevated serum calcium levels. Hypercalcemia may develop either
spontaneously or after administration of vitamin D metabolites or
calcium salts. The most frequent histologic patterns of the under-
lying bone disease in past years were predominant hyperparathy-
roid bone disease and mixed uremic osteodystrophy [1—6]. More
recently, however, states of low bone turnover, particularly ady-
namic bone disease, also referred to as aplastic bone disease, have
been reported in an increasing number of patients on chronic
maintenance dialysis [7—11]. It is not known whether adynamic
bone disease with its decreased bone turnover merely reflects a
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histologic entity or has clinical consequences such as abnormali-
ties in calcium homeostasis.
The goals of the study were to answer whether or not derange-
ments in calcium homeostasis are similar among the three major
histologic forms of renal osteodystrophy and attempt to unravel
factors associated with abnormal calcium metabolism in dialyzed
patients not treated with vitamin D metabolites or calcium salts.
Methods
Patients and protocol
From 1989 to 1991, eighty patients on chronic maintenance
dialysis from the same geographic area were asked to participate
in the study. Inclusion criteria were: age ranging from 18 to 80
years, willingness to undergo an iliac crest bone biopsy, and
willingness to participate in calcium kinetic studies for 28 days.
Exclusion criteria were: treatment with active vitamin D metabo-
lites or calcium salts within the last six months, systemic illnesses
or organ diseases other than diabetes that may affect bone
metabolism (that is, gastrointestinal diseases, liver diseases, etc.),
malignancies, sarcoidosis, tuberculosis, acquired immunodefi-
ciency syndrome, chronic alcoholism, drug addiction, immobiliza-
tion, parathyroidectomy, and bilateral nephrectomy. Also ex-
cluded were patients with a failed transplant within the last six
months and those taking medications known to affect bone
metabolism (diphenyihydantoin, steroids, cyclosporin) during the
last six months.
Forty-three patients were enrolled in the study after informed
consent was obtained. Twenty-seven women and 16 men qualified
and agreed to participate in the study. Twenty-six patients were on
chronic maintenance hemodialysis (HD) and 17 were on contin-
uous ambulatoiy peritoneal dialysis (CAPD). All but two patients
were anuric. Chronic hemodialysis treatment was performed at
the same center three times a week, five hours each time using a
hollow fiber dialyzer with a hemophane (1.3 m2, N = 18; Gambro,
Hechingen, Germany) or polysulfone (0.65 m2, N = 8; Fresenius,
Oberursel, Germany) membrane and MTS 2008 dialysis machine
(Fresenius). The dialysate contained 3.5 mEq/liter calcium and
0.75 mEq/liter magnesium. All patients on CAPD underwent four
two-liter exchanges per day using commercially available dialysate
containing 3.5 mEq!liter of calcium and 0.75 mEq/liter of magne-
sium (Dianeal, Baxter, Munich, Germany).
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Underlying renal diseases were diabetes mellitus (N = 11),
interstitial nephritis (N = 7), chronic glomerulonephritis (N =
11), polycystic kidney disease (N 4), obstructive nephropathy(N = 2), nephrosclerosis (N = 1) and unknown origin (N = 7).
All patients were on an unrestricted diet except for potassium,
phosphate and fluid intake. None of the patients was on recom-
binant human eiythropoeitin. Oral phosphate binders (aluminum
trihydroxide) were given to patients as needed (mean dose: 1,210
mg/day, median 1,320 mg/day, range: 0 to 2,970 mg/day).
At the beginning of the study, all patients underwent iliac crest
bone biopsies with blood drawings for determinations of blood
levels of ionized calcium, phosphorus, alkaline phosphatase, para-
thyroid hormone, 1,25(OH)2D, 25(OH)D and osteocalcin. Cal-
cium kinetic studies were performed during the following 28 days.
Calcium kinetic studies
Calcium kinetic parameters were evaluated by employing a
double isotope technique with radiocalcium. The morning of a
nondialysis day, 0.4 MBq 47Ca was administered intravenously as
carrier-free calcium chloride (Medgenix Diagnostics, Fleurus,
Belgium; specific activity 242 MBq 47Ca/mg Ca, that is, i.v.
administration <100 jg Ca). At the same time, 0.2 MBq 45Ca was
given orally (Medgenix Diagnostics; specific activity 660 MBq
45Ca/mg Ca). This was dissolved in 100 ml of deionized water and
adjusted to a total calcium content of 18 mg by the addition of a
20% calcium gluconate solution. Venous blood samples were
drawn before, and 15, 30, 60, 120, 180 and 240 minutes after
administration. Additional samples were collected after 24 hours
and after seven days. 47Ca in plasma samples was measured in a
well-type Nal (Tl)-scintillation counter, and 45Ca in plasma was
measured by liquid scintillation counting after complete decay of
47Ca [121. Whole body measurements were carried out before the
administration of the radiotracers and two hours, 1, 7, 14, 21, and
28 days thereafter [12}. From these measurements, whole body
retention of intravenously given 47Ca was evaluated as percentage
of initial activity, corrected for radioactive decay [13].
From these measurements, the following parameters were
derived:
(a) Fractional intestinal absorption of calcium, calculated from
the ratio of activities of 45Ca and 47Ca in the blood sample drawn
24 hours after administration.
(b) Plasma calcium efflux, calculated as the ratio of activity
concentrations of the intravenous tracer at 1 and 24 hours after
injection. This empirical parameter reflects the exchange of the
administered tracer with the exchangeable calcium pool and can
be derived directly from the measurements.
(c) The fraction of the intravenously administered tracer re
tamed in the whole body four weeks after administration. This
parameter reflects bone calcium retention and is inversely related
to the total tracer calcium excretion.
(d) The bone accretion. This parameter quantifies the move-
ment of calcium from the exchangeable bone calcium pooi to
mineralized bone; it can be derived from the time course of the
activity curves in plasma and the time course of the whole body
retention curve. The determination of the bone accretion rate
requires the use of a computer for the data fitting procedure and
assumes a catenaly four compartment model to describe the
calcium exchange processes. In this study, the computer code
SAAM-27 [141 run on a SPERRY 1191 computer, was used for
this data analysis. The program determines iteratively a set of
model parameters that provide a best fit to the observed values.
Results were compared to values previously obtained in normal
subjects using the same method [13-451.
Serum biochemical and hormonal determinations
Serum phosphorus, calcium and alkaline phosphatase concen-
trations were determined using standard laboratory techniques
(Hitachi 717 E, Boehringer Mannheim, Germany). Serum para-
thyroid hormone levels were determined in triplicate by the
two-sites immunoradiometric assay (IRMA) for intact PTH [16,
17] using the Allegrom Intact PTH assay kit from Nichols
Institute, Bad Nauheim, Germany. The intra- and inter-assay
coefficients of variation were 7.6% and 9.8%, respectively [16].
Serum levels of 1,25(OH)2D were determined by a radioimmu-
noassay [18]. The intra- and inter-assay coefficients of variation
were 12% and 16.8%, respectively. Serum levels of 25-hydroxyvi-
tamin D [25(OH)D] were measured by competitive protein
binding analysis [19]. Serum osteocalcin levels were determined
with a competitive radioimmunoassay for the determination of
intact human osteocalcin (OSCAtest, Henning, Berlin, Germany).
The intra- and inter-assay coefficients of variation were <10% and
<20%, respectively.
Bone biopsy, mineralized bone histology and histomorphometiy
Prior to biopsies, patients were administered tetracycline hy-
drochloride at a dose of 500 mg b.i.d. for two days. The drug was
discontinued during the following ten days and then given again at
the same dose for another three days. Bone biopsies were
performed four days after the last labeling day. Bone specimens
were taken from the anterior iliac crest using an electric drill
(Institute Straumann, Waldenburg, Switzerland) with an inner
diameter of 5 mm.
Bone samples were processed as previously described [6].
Sections were stained with the modified Masson-Goldner
trichrome stain [20], the aurin tricarboxylic acid stain [21] and
solochrome azurine [22] for detection of aluminum and the
modified Gomori stain for detection of iron [23]. Unstained
sections were prepared for phase contrast and fluorescent light
microscopy.
Static and dynamic parameters of bone structure, formation
and resorption were measured using the Osteoplan system II
(Kontron, Munich, Germany) as previously described [24, 25].
The histologic sections were analyzed after completion of the
study without knowledge of the patients' names or biochemical or
calcium kinetic results. All histomorphometric parameters comply
with the nomenclature and were calculated according to the
ASBMR histomorphometiy nomenclature committee [26].
Patients were also grouped according to the histologic findings
into predominant hyperparathyroid bone disease (severe or mild),
mixed uremic osteodystrophy, low turnover bone disease encom-
passing adynamic bone disease and low turnover osteomalacia as
previously described [6]. Bone biopsies were independently inter-
preted by two investigators. When discrepancies occurred in
borderline cases (less than 1%), additional sections were cut,
reviewed, discussed and assigned to one of the three categories.
Statistical analysis
Results are expressed as means SEM. Differences in continu-
ous variables were assessed by standard analysis of variance.
When a significant F value was obtained, difference between
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Table 1. Demographic and clinical characteristics of 43 dialyzed
patients according to histologic groups of renal osteodystrophy
Predominant
Low turnover
bone disease
Mixed uremic
osteodystrophy
hyperparathyroid
bone disease
Number of 16 20 7
patients
Men/women 9/7 4/16 3/4
Mode of
dialysis
HD/CAPD 10/6 10/10 6/1
Diabetics/ 5/11 6/14 0/7
nondiabetics
Age (years) 64.8 3.2 (67) 60.4 2.6 (63) 42,6b 5.6 (43)
Range
Duration of
32—78
14.2a 4.9 (8)
31-78
18.5a 6.4 (4)
23—59
534b 16.8 (71)
dialysis
(months)
Range 1—65 1—112 1—108
Number of 6 9 3
patients with
positive SBA
% of trabecular 64 9 (67) 57 7 (52) 47 8 (47)
surface in
SBA-positive
patients
Range 30—94 31—85 32—61
Results are given as mean SEM (median).
Positive SBA is stainable aluminum of the bone-osteoid interface/bone
surface.
a,b Values with different letters are statistically significant (P < 0.01) by
one-way analysis of variance with Scheffe post hoc test
means was determined by the Scheffe post hoc test. Differences in
distribution were analyzed using the Chi-square test. Regression
analyses, calculations of coefficients of correlation and partial
correlation coefficients were performed. All tests were two-sided,
Computations were done using SPSS software V3.1 (SPSS, mc,
Chicago, Illinois, USA) on an IBM PS computer, model 60.
Results
Characteristics of patients enrolled in the study
The patients enrolled in the study exhibited the typical patterns
of renal osteodystrophy (Table 1). In addition to the known
histomorphometric differences between the three histologic
groups—predominant hyperparathyroid bone disease (PHBD),
mixed uremic osteodystrophy (MUO) and low turnover bone
disease (LTBD) [6]—bone volume/tissue volume was significantly
higher in patients with PHBD (35.5 5.6%) than in the other
patients (MUO = 21.9 1.3%, LTBD = 18.1 1.2, P < 0.001).
No difference in demographic or clinical characteristics was
found when patients were grouped according to their mode of
dialysis, gender or underlying kidney disease. Also, no differences
in prevalence and extent of bone aluminum deposition were
observed between the histologic groups (Table 1) or between men
and women, various modes of dialysis or presence or absence of
diabetes.
Biochemical results in the three histological groups are shown
in Table 2. Hypercalcemia was found in patients with LTBD (N =
3) and MUO (N = 2) and in only one patient with PHBD.
Parathyroid hormone concentrations were statistically different
among the three histologic groups, (Table 2). All patients with
MUO and PHBD had serum parathyroid hormone values above
the normal range and patients with LTBD had either normal
(N = 6) or elevated (N = 10) levels, When serum biochemical and
hormonal results were analyzed according to gender, diabetes or
bone aluminum accumulation, no differences were found either
overall or within each histologic group.
The known relationships between serum levels of parathyroid
hormone, alkaline phosphatase and osteocalcin in patients with
end-stage renal disease [6] were also observed in the population
studied (r ranging from 0.73 to 0.88, P < 0.001). Similarly, serum
parathyroid hormone and alkaline phosphatase levels showed the
previously reported [27, 28] good relationship with histomorpho-
metric parameters of bone formation, resorption and turnover
(r ranging from 0.61 to 0.74, P < 0.01). Osteocalcin levels
displayed a positive relationship with parameters of bone forma-
tion (r ranging from 0.75 to 0.85, P < 0.001) [29].
Calcium kinetic studies
All but one patient had intestinal calcium absorption below the
normal range. There was no difference in calcium absorption
among the three histologic groups and calcium absorption was
significantly lower in women than in men regardless of the
histologic group (Fig. 1). The only patient exhibiting normal
intestinal calcium absorption had LTBD and was hypercalcemic.
No difference in intestinal calcium absorption was observed
between diabetic and nondiabetic patients, patients undergoing
HD or CAPD and patients with or without bone aluminum
accumulation.
Plasma calcium efflux and calcium accretion rate were signifi-
cantly higher in the patients with PHBD than in the two other
groups, and did not differ between LTBD and MUO (Figs. 2 and
3). There was no difference in plasma calcium efflux and calcium
accretion rate between men and women, diabetic and nondiabetic
patients, presence or absence of aluminum deposition in bone
overall or within each histologic group. Calcium retention was
statistically different among the three groups; however, consider-
able overlap did not allow to differentiate the three histologic
groups (Fig. 4). One patient with PHBD exhibited calcium
retention below normal; he also had the highest aluminum
deposition at the bone osteoid interface (61%) and the lowest
bone volume (18%) in this group. No difference in calcium
retention was observed when results were analyzed according to
gender, mode of dialysis, kidney diseases or degree of aluminum
accumulation.
Correlations between calcium kinetics, serum biochemistiy and
bone morphometiy
There were positive correlations between plasma calcium effiux,
calcium accretion rate and calcium retention (Table 3) but no
correlation with intestinal calcium absorption. Plasma calcium
efflux, calcium accretion rate and calcium retention correlated
positively with serum levels of alkaline phosphatase and parathy-
roid hormone (Table 3). Similarly, with a lower number of
patients (N = 20), there were positive correlations between
osteocalcin and plasma calcium efflux, calcium accretion rate and
calcium retention (Table 3). No relationships were found between
the three parameters of calcium kinetics and serum concentra-
tions of ionized calcium, phosphorus, 1,25(OH)2D and 25(OH)D.
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Table 2. Biochemical parameters in 43 dialyzed patients according to histologic groups of renal osteodystrophy
Predominant
Low turnover
bone disease
Mixed uremic
osteodystrophy
hyperparathyroid
bone disease
Normal
values
Ionized calcium mmol/liter 1.1 0.06 (Li) 1.oa 0.05 (1.0) 1.2 0.08(1.1) 1.05—1.3
Range 0.6—1.5 0.6—1.3 1.1—1.6
Phosphorus mg/dl 5.7 0.25 (5.3) 5.2 0.35 (5.3) 5•4a 0.46 (5.3) 2.5—4.8
Range 4.3—7.8 1.9—8.3 3.4—7.5
Alkaline phosphatase U/liter 111 8.0 (106) 191U 18.6 (162) 700" 145 (823) <190
Range 55—162 100—405 86—1214
Parathyroid hormone pg/mt
Range
116 30(61)
28—390
575" 99(543)
66—2067
1275C 130 (1276)
924—1962
10—55
Osteocalcin pg/liter i0.6a 2.64 (10) 26.5a 8.61 (15) 95.0" 7.00 (95) 1.8—6.6
Range 2.7—22.0 6.0—99.9 88 —102
1,25 Vitamin D ng/liter 24.5 2.56 (24) 25.8a 3.68 (21) 23.4 3.45 (19) 35—90
Range 10—43 13—79 16—39
25 Vitamin D pmol/liter 55.5 15.6 (26) 41.2 6.6 (38) 76.5u 19.7 (76) 50—300
Range 10—201 10—106 27—130
Results are given as mean SCM (median).
a,b,c Values with different letters are statistically significantly different (P < 0.01) by one-way analysis of variance with Scheffe post hoc test
d Osteocalcin measurements were obtained in a subset of 20 patients
LTBD MUO
Fig. 1. Intestinal calcium absorption in 43 dialyzed patients with low
turnover bone disease (LTBD), mixed uremic osteodystrophy (MUO) and
predominant hyperparathyroid bone disease (PHBD). Bars indicate mean
values of intestinal calcium absorption. Error bars represent SEM. Aster-
isks indicate a significant difference between the values for men and
women (P < 0.01, Student t-test).
There were positive relationships between calcium accretion
rate, calcium retention and normal and pathologic parameters of
bone formation, resorption and turnover (Table 4). The observed
positive relationships between calcium accretion rate, calcium
retention and bone volume were not significantly changed when
partial correlation analysis controlling for bone volume was
performed (Table 4). Calcium absorption did not show significant
correlations with any histomorphometric parameters of bone, and
none of the four indices of calcium kinetics demonstrated any
relationship with the extent of stainable aluminum deposition.
Regression analysis showed that only serum levels of parathyroid
hormone (PTH) had a significant relationship with plasma cal-
cium effiux (r2 = 0.46, plasma calcium efflux = 2.12 + 0.012 PTH,
P < 0.001). For calcium accretion rate, bone volume/tissue
volume (BV/TV) and plasma calcium efflux (PCa-eff) entered the
/ / / / / / / z / / / / / / / / / / / / J
LTBD MUO PHBD
Histologic groups
Fig. 2. Plasma calcium efflux values in 43 dialyzed patients with low
turnover bone disease (LTBD), mixed uremic osteodystrophy (MUO) and
predominant hyperparathyroid bone disease (PHBD). Horizontal lines indi-
cate mean values of plasma calcium efilux for each group. Mean value of
patients with PHBD was statistically different from the two other groups
(P < 0.001, ANOVA). Shaded area indicates normal range.
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equation (calcium accretion rate 99 BV/TV + 690 PCa-eff —
3298, P < 0.001). Calcium retention was predicted by serum levels
of 1,25D and PTH and calcium accretion rate (Ca-acer) (calcium
retention = 0.60 1,25D + 0.13 PTH + 0.006 Ca-acer, P < 0.001).
Discussion
The results of the present study show that the various histologic
forms of renal osteodystrophy are accompanied by different
alterations in their calcium kinetic profiles and their abilities to
handle calcium exchanges between the various compartments.
The only common aspect observed among the three histologic
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Fig. 3. Calcium accretion rate values in 43 dialyzed patients with low
turnover bone disease (LTBD), mixed uremic osteodystrophy (MUO) and
predominant hyperparathyroid bone disease (PHBD). The horizontal lines
indicate mean values of plasma calcium effiux for each group. Mean value
of patients with PHBD was statistically different from the two other groups
(P < 0.001, ANOVA). Shaded area indicates normal range.
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Fig. 4. Calcium retention values in 43 dialyzed patients with low turnover
bone disease (LTBD), mixed uremic osteodystrophy (MUO) and predomi-
nant hyperparathyroid bone disease (PHBD). The horizontal lines indicate
mean values of plasma calcium effiux for each group. All means were
statistically different from each other group (P < 0.001, ANOVA). Shaded
area indicates normal range.
Table 3. Coefficients of correlation between various parameters of
calcium kinetics in 43 patients with end-stage renal failure
Calcium
absorption
Plasma
calcium
effiux
Calcium
accretion
rate
Calcium
retention
Alkaline phosphatase —0.08 0.85" 0.86" 0.76"
Parathyroid hormone
Osteocalcin"
—0.08
—0.02
0.70"
070b
0.66"
0.72a
0.77a
0.73a
Calcium absorption —0.04 —0.03 0.01
Plasma calcium effiux 0.86" 0.76a
Calcium accretion rate 086a
"p <0.001
bp <0.01
Osteocalcin levels were available in a subset of 20 patients
Table 4. Coefficients of correlation (r) and partial correlation
coefficients controlling for bone volume (Partial r) between
histomorphometric parameters of bone and calcium kinetic results in 43
patients with end-stage renal failure
Calcium Calcium Plasma calcium
accretion rate retention effiux
Parameters of Partial Partial Partial
bone r r r r r r
Bone volume! 0.60"" — 0.68" — 0.61" —
tissue volume
Osteoid volume! 0.76" 054b 0.74" 0.42 0.65a 0.38
bone volume
Woven osteoid 0.81" 068b 0.66a 0.37 0.66" 0.44
surface!
bone surface
Osteoblast 0.76" 063b 0.76a 0.51' 0.69" 0.41
number
Fibrosis surface! 0.93" 0.81" 0.70" 0.23 0.86" 0.76"
bone surface
Osteoclast 0.80" Ø57t 0.79" 0.50" 0.79" 0.42
number!
bone length
Mineralization lag —0.29 —0.42 —0.46 —0.31 —0.15 —0.29
time
Bone formation 0.76" 0.57" 0.73" 0.52" 0.52 0.12
rate!
bone surface
Activation 0.73" 057b 0.74" 0.53" 0.38 0.01
frequency
10.0
3.02.0
a)
1.5
0
a)
8 1.0
cci
E
0.5
0
0
0
0
0
LTBD PHBD
0
0
C0
C
a)
ci)
E
C)
cci0
100
80
60
40
20
0
0
8
LTBD MUO PHBD
forms is an intestinal calcium absorption below the normal range
in patients with end-stage renal failure which confirms well-
established previous observations [13, 30—33]. We found intestinal
calcium absorption equally low among patients exhibiting the
different histologic forms of renal osteodystrophy in the absence
of administration of calcium salts or 1,25(OH)2D3. This finding
differs from a previously observed trend towards higher values of
calcium absorption in patients with severe "osteitis fibrosa" [33].
The present study provides the novel information that female
ap <0.05
bp < 0.001
"P < 0.01
patients with end-stage renal failure have lower intestinal calcium
absorption than male patients regardless of the histologic groups
of renal osteodystrophy and despite no difference in serum levels
of 1,25(OH)2D and parathyroid hormone between men and
women. A previous study comparing intestinal calcium absorption
between normal men and women did not show this difference [12].
However, in this study by Werner, Roth and Malluche [12] the
male and female normal volunteers were much younger than the
patients enrolled in our study which included 23 women of pen- or
postmenopausal ages and no women with menstrual cycles. This
may ascribe a role to estrogen deficiency in the impaired intestinal
calcium absorption, in addition to the decrease in production of
1,25(OH)D in women with end-stage renal failure. It is tempting
to hypothesize a vitamin D-independent action of estrogen on
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intestinal calcium absorption in women with renal failure as it was
shown in oophorectomized women with normal renal function
[34].
Patients with severe hyperparathyroid bone disease have mark-
edly elevated plasma calcium efflux, calcium accretion rate and
calcium retention. This indicates that when calcium balance is
normal or positive, these patients have the ability to increase
mineralized bone volume utilizing their higher bone formation
rates. Calcium retention was found to be influenced by the
quantity of exchangeable calcium present in bone (calcium accre-
tion rate) and serum levels of parathyroid hormone and
1,25(OH)D. This finding agrees with previous studies which
showed that both hormones are needed to obtain efficient bone
formation [35—37] because parathyroid hormone controls bone
turnover, therefore the numbers of bone cells, and 1,25(OH)D
stimulates the activity of individual osteoblasts in forming and
mineralizing bone [37]. Conversely, a marked decrease in calcium
retention was reported several months after parathyroidectomy
[38]. However, the capacity of bone to absorb extra calcium may
be overcome in these states of high turnover when osteoblastic
activity is impaired by profound deficiency in 1,25(OH)D or toxic
effects such as aluminum and possibly other factors. This results in
an imbalance between bone formation and resorption leading to
a diminished capacity of bone to buffer extra calcium. Also,
long-term administration of calcium salts and/or treatment with
yitamin D metabolites will decrease bone turnover, and the
calcium kinetic profile might shift toward the ones observed in the
other histologic groups, that is, lower calcium retention without a
change in intestinal calcium absorption.
Patients with low turnover bone disease exhibited normal to low
plasma calcium effiux and calcium accretion rate—indices of the
rapidly exchangeable calcium pool. This contrasts with the
marked reduction in bone calcium retention. Therefore, when
subjected to calcium loads, patients with LTBD are unable to
incorporate the extra calcium into the mineralized matrix of bone,
and the total exchangeable calcium pool will increase which may
result in hypercalcemia and/or extraosseous calcifications. In
analogy, Meric, Yap and Bia [39} found that dialyzed patients
treated with calcium carbonate are at higher risk for developing
hypercalcemia when serum indices of bone turnover such as
parathyroid hormone, osteocalcin and alkaline phosphatase were
low. Consequently, administration of calcium salts for phosphate
binding through increased passive intestinal calcium absorption
[40] or therapy with metabolites of vitamin D by stimulation of
active intestinal absorption of calcium [41] carries the potential
risk of overloading the total exchangeable extracellular calcium
pool with its risk of inducing hypercalcemia and/or soft tissue
calcifications.
Analogous to bone histology, calcium kinetic profiles in patients
with MUO lie between those of patients with PHBD and LTBD.
Patients with MUO have a greater bone capacity to retain calcium
than patients with LTBD; however, when challenged with a
calcium load the underlying bone turnover and osteoblastic vigor
will determine their ability to react.
The different calcium kinetic profiles among the three histo-
logic groups and their good relationships with bone histology
confirm the importance of the distinction among histologic groups
in managing patients with renal osteodystrophy. In particular,
adynamic bone disease does not merely represent an academic
finding. In fact, it is characterized by a vety low bone capacity to
buffer calcium and an inability to handle an extra calcium load.
This finding is of particular relevance since higher amounts of
vitamin D and higher doses of calcium salts are presently used in
the daily care of patients with end-stage renal failure. Identifying
states of low bone turnover and poor calcium retention is of great
clinical value in the decision to institute or discontinue therapy
with calcium salts or vitamin D. Although in our study serum
parathyroid hormone levels correlated well with histomorphomet-
nc parameters of bone turnover and calcium kinetics, it is of note
that in the present study, patients with LTBD presented with
serum concentrations of parathyroid hormone up to 390 pg/mi.
This level represents more than seven times the upper normal
range. Further studies are needed to clarit' whether other mea-
surable systemic substances control bone turnover or whether
local factors of the microenvironment in bone such as cytokines or
growth factors are primary regulators of bone turnover.
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